Background: Nephrotic syndrome is an important chronic disease in Pediatrics which commonly tends to relapse. Corticosteroids represent the main line of treatment. However, many cases are either resistant to treatment or experience major side effects to treatment. Mycophenolate (MMF) represents a new safer immunosuppressive. Methodology: a systematic review of available studies addressing the use of MMF in either SRNS or FR/SDNS was conducted. Relevant studies were appraised for quality and results from eligible studies were collected and analyzed. Results: Based on evidence from prospective non-randomized studies, MMF decreases both relapses and steroid requirements in children with FRNS and SDNS similar to CsA. MMF induced a complete remission slightly more than CsA. Conclusion: MMF is useful in both SD/FRNS and SRNS with less side effects. RCTs or prospective cohort are needed to address the use of MMF in pediatric nephrotic syndrome.